Levobunolol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Ocular HTN; Open-angle glaucoma As 0.25% drops: Instill 1-2 drops in the affected eye(s) bid. As 0.5% drops: Instill 1-2 drops in the affected eye(s) once daily, may increase to 1 drop bid.
Dosage Details
Ophthalmic
Ocular hypertension, Open-angle glaucoma
Adult: As 0.25% drops: Instill 1-2 drops in the affected eye(s) bid. As 0.5% drops: Instill 1-2 drops in the affected eye(s) once daily, may increase to 1 drop bid.
Contraindications
Sick sinus syndrome, sinus bradycardia, 2nd and 3rd degree AV block, asthma or history of asthma, severe COPD, cardiogenic shock, overt cardiac failure.
Special Precautions
Patients w/ diminished pulmonary function, nonallergic bronchospasm, inadequate cardiac function, DM, myasthenia gravis. May mask signs and symptoms of hypoglycaemia and hyperthyroidism. Avoid abrupt withdrawal as it may precipitate thyroid storm. Pregnancy and lactation.
Adverse Reactions
Ocular stinging, burning, blepharoconjunctivitis, blepharitis, decreased visual acuity, band keratopathy, erythema, iridocyclitis, conjunctivitis and itching sensation; bradycardia, CVA, syncope, arrhythmia, heart block, hypotension, cerebral ischaemia, bronchospasm. Rarely, reduced corneal sensitivity and tearing.
Patient Counseling Information
Do not drive or operate machinery until vision is clear.
Drug Interactions
Additive hypotensive effect w/ catecholamine-depleting drug (e.g. reserpine), Ca channel blockers, β-adrenergic blockers, digitalis glycosides, antiarrhythmics, guanethidine, parasympathomimetics. Mydriasis may occur when used w/ epinephrine.
Action
Description: Levobunolol is a nonselective β-adrenergic blocking agent. It causes the reduction of intraocular pressure by decreasing the production of aqueous humour.
Onset: W/in 1 hr.
Duration: Up to 24 hr.
Pharmacokinetics:
Absorption: Some absorbed systematically.
Storage
Store between 15-30°C. Protect from light.
Disclaimer: This information is independently developed by MIMS based on Levobunolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Betagan
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in